DE3481913D1
(de)
*
|
1983-04-27 |
1990-05-17 |
Ici America Inc |
Prolin-derivate.
|
FR2663336B1
(fr)
|
1990-06-18 |
1992-09-04 |
Adir |
Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
|
FR2713225B1
(fr)
|
1993-12-02 |
1996-03-01 |
Sanofi Sa |
N-pipéridino-3-pyrazolecarboxamide substitué.
|
US5631365A
(en)
*
|
1993-09-21 |
1997-05-20 |
Schering Corporation |
Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
|
US5656624A
(en)
*
|
1994-12-21 |
1997-08-12 |
Schering Corporation |
4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
|
WO1997016455A1
(en)
|
1995-10-31 |
1997-05-09 |
Schering Corporation |
Sugar-substituted 2-azetidinones useful as hypocholesterolemic a gents
|
AU727775B2
(en)
|
1996-01-17 |
2000-12-21 |
Novo Nordisk A/S |
Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
|
US6225310B1
(en)
*
|
1996-01-17 |
2001-05-01 |
Novo Nordisk A/S |
Fused 1,2,4-thiadiazine derivatives, their preparation and use
|
US5739321A
(en)
|
1996-05-31 |
1998-04-14 |
Schering Corporation |
3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
|
PT944648E
(pt)
|
1996-08-30 |
2007-06-26 |
Novo Nordisk As |
Derivados do glp-1.
|
US6268343B1
(en)
*
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US5756470A
(en)
*
|
1996-10-29 |
1998-05-26 |
Schering Corporation |
Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
|
EP0958296B1
(en)
|
1996-12-31 |
2003-07-30 |
Dr. Reddy's Laboratories Ltd. |
Heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
|
DE19726167B4
(de)
|
1997-06-20 |
2008-01-24 |
Sanofi-Aventis Deutschland Gmbh |
Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
|
BR9810592A
(pt)
|
1997-07-16 |
2000-09-12 |
Novo Nordisk As |
Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto
|
CO4970713A1
(es)
|
1997-09-19 |
2000-11-07 |
Sanofi Synthelabo |
Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
|
DE69917237T2
(de)
|
1998-03-12 |
2005-05-04 |
Teijin Ltd. |
Benzofurylpyron-derivate
|
US6221897B1
(en)
|
1998-06-10 |
2001-04-24 |
Aventis Pharma Deutschland Gmbh |
Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
|
DE19845405C2
(de)
|
1998-10-02 |
2000-07-13 |
Aventis Pharma Gmbh |
Arylsubstituierte Propanolaminderivate und deren Verwendung
|
BR9915961A
(pt)
|
1998-12-07 |
2001-08-21 |
Sod Conseils Rech Applic |
Análogos de glp-1
|
GB9900416D0
(en)
|
1999-01-08 |
1999-02-24 |
Alizyme Therapeutics Ltd |
Inhibitors
|
DE19916108C1
(de)
|
1999-04-09 |
2001-01-11 |
Aventis Pharma Gmbh |
Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
|
WO2000063703A1
(en)
|
1999-04-16 |
2000-10-26 |
Schering Corporation |
Use of azetidinone compounds
|
PT1177176E
(pt)
|
1999-04-28 |
2006-08-31 |
Aventis Pharma Gmbh |
Derivados de acidos triarilicos como ligandos de receptores ppar.
|
SK15532001A3
(sk)
|
1999-04-28 |
2002-06-04 |
Aventis Pharma Deutschland Gmbh |
Deriváty kyselín s dvoma arylovými zvyškami ako ligandy receptorov PPAR a farmaceutické kompozície, ktoré ich obsahujú
|
GB9911863D0
(en)
|
1999-05-21 |
1999-07-21 |
Knoll Ag |
Therapeutic agents
|
CA2376919C
(en)
|
1999-06-18 |
2008-11-04 |
Merck & Co., Inc. |
Arylthiazolidinedione and aryloxazolidinedione derivatives
|
EP1076066A1
(en)
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides for lowering blood glucose levels
|
DK1204654T3
(da)
|
1999-07-29 |
2003-11-17 |
Lilly Co Eli |
Benzofurylpiperaziner og benzofurylhomopiperaziner: Serotonin agonister
|
DK1218341T3
(da)
|
1999-09-01 |
2005-12-12 |
Sanofi Aventis Deutschland |
Sulfonylcarboxamid-derivater, fremgangsmåde til deres fremstilling og deres anvendelse som lægemiddel
|
PE20011010A1
(es)
|
1999-12-02 |
2001-10-18 |
Glaxo Group Ltd |
Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
|
EP1259246A2
(en)
|
2000-02-25 |
2002-11-27 |
Novo Nordisk A/S |
Use of dpp-iv inhibitors for the treatment of diabetes
|
CA2407538C
(en)
*
|
2000-04-28 |
2007-01-09 |
Asahi Kasei Kabushiki Kaisha |
Novel bicyclic compounds
|
EP1280777B1
(en)
|
2000-05-11 |
2005-11-23 |
Bristol-Myers Squibb Company |
Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
|
SE0001899D0
(sv)
|
2000-05-22 |
2000-05-22 |
Pharmacia & Upjohn Ab |
New compounds
|
DE60128475T2
(de)
*
|
2000-07-25 |
2008-02-07 |
Merck & Co., Inc. |
N-substituierte indole mit anwendung in der behandlung von diabetes
|
HUP0004741A2
(hu)
|
2000-11-28 |
2002-12-28 |
Sanofi-Synthelabo |
Kémiai eljárás tiazolszármazékok előállítására és új intermedier
|
HUP0401073A2
(hu)
|
2000-12-21 |
2004-09-28 |
Aventis Pharma Deutschland Gmbh. |
Difenilazetidinon-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
|
AU1609702A
(en)
*
|
2000-12-21 |
2002-07-01 |
Aventis Pharma Gmbh |
Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
|
IL156552A0
(en)
*
|
2000-12-21 |
2004-01-04 |
Aventis Pharma Gmbh |
Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
|
TWI291957B
(en)
|
2001-02-23 |
2008-01-01 |
Kotobuki Pharmaceutical Co Ltd |
Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
|
GB0113233D0
(en)
|
2001-05-31 |
2001-07-25 |
Glaxo Group Ltd |
Chemical compounds
|
DE10139416A1
(de)
*
|
2001-08-17 |
2003-03-06 |
Aventis Pharma Gmbh |
Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
US6884812B2
(en)
*
|
2001-08-31 |
2005-04-26 |
Aventis Pharma Deutschland Gmbh |
Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
|
KR100915108B1
(ko)
|
2001-08-31 |
2009-09-03 |
사노피-아벤티스 도이칠란트 게엠베하 |
Ppar-활성화제로서의 디아릴사이클로알킬 유도체 및 이를 포함하는 약제학적 조성물
|
IL164249A0
(en)
|
2002-04-11 |
2005-12-18 |
Aventis Pharma Gmbh |
Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use
|
AU2003234929A1
(en)
|
2002-05-17 |
2003-12-02 |
Kyowa Hakko Kogyo Co., Ltd. |
Therapeutic agent for diabetes
|
US7176193B2
(en)
*
|
2002-06-19 |
2007-02-13 |
Sanofi-Aventis Deutschland Gmbh |
Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
|
DE10227508A1
(de)
|
2002-06-19 |
2004-01-08 |
Aventis Pharma Deutschland Gmbh |
Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
DE10227506A1
(de)
|
2002-06-19 |
2004-01-08 |
Aventis Pharma Deutschland Gmbh |
Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
US7176194B2
(en)
*
|
2002-06-19 |
2007-02-13 |
Sanofi-Aventis Deutschland Gmbh |
Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
|
DE10227507A1
(de)
|
2002-06-19 |
2004-01-08 |
Aventis Pharma Deutschland Gmbh |
Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
US7671047B2
(en)
*
|
2002-06-19 |
2010-03-02 |
Sanofi-Aventis Deutschland Gmbh |
Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
|
GB0215579D0
(en)
*
|
2002-07-05 |
2002-08-14 |
Astrazeneca Ab |
Chemical compounds
|
AU2003249937A1
(en)
|
2002-07-12 |
2004-02-02 |
Sanofi-Aventis Deutschland Gmbh |
Heterocyclically substituted benzoylureas, method for their production and their use as medicaments
|
DE10314610A1
(de)
|
2003-04-01 |
2004-11-04 |
Aventis Pharma Deutschland Gmbh |
Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
|
JP4531696B2
(ja)
|
2003-04-25 |
2010-08-25 |
パナソニック株式会社 |
マルチメディア情報共有システム
|
JP2005015434A
(ja)
|
2003-06-27 |
2005-01-20 |
Kotobuki Seiyaku Kk |
血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
|
KR20060052792A
(ko)
|
2003-07-09 |
2006-05-19 |
포비스 메디-테크 인코포레이티드 |
신규 화합물 및 스테롤 및/또는 스탄올 및 콜레스테롤생합성 억제제를 포함하는 조성물 및 다양한 질병 및증상을 치료 또는 예방하기 위한 이들의 용도
|
WO2005005477A2
(en)
|
2003-07-11 |
2005-01-20 |
Novo Nordisk A/S |
Stabilised insulin compositions
|
WO2005021495A2
(en)
|
2003-08-25 |
2005-03-10 |
Microbia Inc. |
Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones
|
WO2005021497A2
(en)
|
2003-08-28 |
2005-03-10 |
Microbia, Inc. |
Tethered dimers and trimers of 1,4-diphenylazetidn-2-ones
|
WO2005027978A2
(en)
|
2003-09-19 |
2005-03-31 |
Novo Nordisk A/S |
Albumin-binding derivatives of therapeutic peptides
|
EP1522541A1
(en)
|
2003-10-07 |
2005-04-13 |
Lipideon Biotechnology AG |
Novel hypocholesterolemic compounds
|
CN1870988A
(zh)
|
2003-10-30 |
2006-11-29 |
默克公司 |
作为抗高胆固醇血症药的2-氮杂环丁烷酮
|
WO2005042692A2
(en)
|
2003-10-31 |
2005-05-12 |
Forbes Medi-Tech Inc. |
A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors
|
PT1682499E
(pt)
|
2003-11-10 |
2007-11-05 |
Microbia Inc |
4-biarilil-1-fenilazetidin-2-onas
|
WO2005061452A1
(en)
|
2003-12-23 |
2005-07-07 |
Astrazeneca Ab |
Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
|
EP1699760B1
(en)
|
2003-12-23 |
2017-05-17 |
Merck Sharp & Dohme Corp. |
Anti-hypercholesterolemic compounds
|
GB0329778D0
(en)
|
2003-12-23 |
2004-01-28 |
Astrazeneca Ab |
Chemical compounds
|
JP2007517800A
(ja)
|
2004-01-06 |
2007-07-05 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
糖尿病および肥満を処置するためのグリコーゲンホスホリラーゼインヒビターとしての(3−オキソ−3,4−ジヒドロ−キノキサリン−2−イル−アミノ)−ベンズアミド誘導体および関連化合物
|
DE102004006325A1
(de)
|
2004-02-10 |
2005-08-25 |
Bayer Healthcare Ag |
Tetrahydrobenzo[d]azepin-2-on-Derivate und ihre Verwendung
|
US7504400B2
(en)
|
2004-03-10 |
2009-03-17 |
Janssen Pharmaceutica N.V. |
MTP inhibiting aryl piperydines or piperazines substituted with 5-membered heterocycles
|
JPWO2005097738A1
(ja)
|
2004-04-06 |
2008-02-28 |
大日本住友製薬株式会社 |
新規スルホンアミド誘導体
|
WO2005097076A2
(en)
|
2004-04-09 |
2005-10-20 |
Smithkline Beecham Corporation |
Low dose pharmaceutical products
|
DE102004025072A1
(de)
*
|
2004-05-21 |
2005-12-15 |
Sanofi-Aventis Deutschland Gmbh |
Verfahren zur Herstellung von Diphenyl-azetidinon-Derivaten
|
FR2871463B1
(fr)
|
2004-06-11 |
2006-09-22 |
Merck Sante Soc Par Actions Si |
Derives a structure aroyl-o-piperidine, leurs procedes de preparation, les compositions pharmaceutiques qui les contiennent et leurs applications en therapeutique
|
EP1761521A1
(en)
|
2004-06-24 |
2007-03-14 |
Eli Lilly And Company |
Compounds and methods for treating dyslipidemia
|
WO2006017257A2
(en)
|
2004-07-12 |
2006-02-16 |
Phenomix Corporation |
Azetidinone derivatives
|
FR2873368B1
(fr)
|
2004-07-26 |
2008-01-04 |
Merck Sante Soc Par Actions Si |
Derives de guanidine et leurs utilisations en therapeutique
|
FR2873694B1
(fr)
|
2004-07-27 |
2006-12-08 |
Merck Sante Soc Par Actions Si |
Nouveaux aza-indoles inhibiteurs de la mtp et apob
|
WO2006029699A1
(en)
|
2004-09-11 |
2006-03-23 |
Sanofi-Aventis Deutschland Gmbh |
7-azaindoles and their use as ppar agonists
|
WO2006037810A2
(en)
|
2004-10-07 |
2006-04-13 |
Novo Nordisk A/S |
Protracted glp-1 compounds
|
JP5107713B2
(ja)
|
2004-10-07 |
2012-12-26 |
ノヴォ ノルディスク アー/エス |
遅延性のエキセンディン−4化合物
|
WO2006045564A1
(en)
|
2004-10-22 |
2006-05-04 |
Smithkline Beecham Corporation |
Xanthine derivatives with hm74a receptor activity
|
RU2007118932A
(ru)
|
2004-10-22 |
2008-11-27 |
Смитклайн Бичам Корпорейшн (US) |
Производные ксантина с активностью нм74а
|
WO2006059744A1
(ja)
|
2004-11-30 |
2006-06-08 |
Nippon Chemiphar Co., Ltd. |
ペルオキシソーム増殖剤活性化受容体δの活性化剤
|
BRPI0519566A2
(pt)
|
2004-12-18 |
2009-01-27 |
Bayer Healthcare Ag |
derivados de (5s)-3-[(s)-fléor(4-trifluormetilfenil)metil]-5,6,7,8-tet raidroquinolin-5-ol e seu uso como inibidores de cetp
|
PE20060949A1
(es)
|
2004-12-23 |
2006-10-11 |
Arena Pharm Inc |
Derivados fusionados de pirazol como agonistas del receptor de niacina
|
EP1838311A1
(en)
|
2004-12-24 |
2007-10-03 |
Prosidion Limited |
G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes
|
EP1838706A1
(en)
|
2004-12-24 |
2007-10-03 |
Prosidion Limited |
G-protein coupled receptor agonists
|
ES2644450T3
(es)
|
2004-12-31 |
2017-11-29 |
Dr. Reddy's Laboratories Ltd. |
Nuevos derivados de bencilamina como inhibidores de CETP
|
DE102005000666B3
(de)
|
2005-01-04 |
2006-10-05 |
Sanofi-Aventis Deutschland Gmbh |
Sulfonylpyrrolidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
WO2006084176A2
(en)
|
2005-02-03 |
2006-08-10 |
Irm Llc |
Compounds and compositions as ppar modulators
|
EP1851197A2
(en)
|
2005-02-09 |
2007-11-07 |
Microbia, Inc. |
Phenylazetidinone derivatives
|
FR2883000B1
(fr)
|
2005-03-14 |
2007-06-01 |
Merck Sante Soc Par Actions Si |
Derives de trifluoromethylbenzamide et leurs utilisations en therapeutique
|
US20090186834A1
(en)
|
2005-03-24 |
2009-07-23 |
Microbia, Inc. |
Diphenylheterocycle cholesterol absorption inhibitors
|
AU2006236939A1
(en)
|
2005-04-13 |
2006-10-26 |
Merck Sharp & Dohme Corp. |
Niacin receptor agonists, compositions containing such compounds and methods of treatment
|
US20080194494A1
(en)
|
2005-04-26 |
2008-08-14 |
Microbia, Inc. |
4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia
|
EP1877373A2
(en)
|
2005-05-05 |
2008-01-16 |
Microbia, Inc. |
Biphenylazetidinone cholesterol absorption inhibitors
|
JP2008539735A
(ja)
|
2005-05-06 |
2008-11-20 |
バイエル・フアーマシユーチカルズ・コーポレーシヨン |
グルカゴン様ペプチド1(glp−1)受容体アンタゴニストおよびそれらの薬理学的使用方法
|
EP1879860A2
(en)
|
2005-05-10 |
2008-01-23 |
Microbia Inc. |
1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia
|
AU2006244043A1
(en)
|
2005-05-11 |
2006-11-16 |
Microbia, Inc. |
Processes for production of phenolic 4-biphenylylazetidin-2-ones
|
ES2350852T3
(es)
|
2005-05-13 |
2011-01-27 |
Eli Lilly And Company |
Compuestos glp-1 pegilados.
|
AU2006247695B2
(en)
|
2005-05-17 |
2012-08-09 |
Merck Sharp & Dohme Corp. |
Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
|
BRPI0611415A2
(pt)
|
2005-05-25 |
2010-09-08 |
Microbia Inc |
ácidos fosfÈnicos de 4-(bifenilil)azetidin-2-ona e processo para a produção dos mesmos
|
CN101198338A
(zh)
|
2005-06-15 |
2008-06-11 |
默克公司 |
抗高胆固醇血化合物
|
UY29607A1
(es)
|
2005-06-20 |
2007-01-31 |
Astrazeneca Ab |
Compuestos quimicos
|
SA06270191B1
(ar)
|
2005-06-22 |
2010-03-29 |
استرازينيكا ايه بي |
مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
|
AR057072A1
(es)
|
2005-06-22 |
2007-11-14 |
Astrazeneca Ab |
Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
|
AR054482A1
(es)
|
2005-06-22 |
2007-06-27 |
Astrazeneca Ab |
Derivados de azetidinona para el tratamiento de hiperlipidemias
|
AR057380A1
(es)
|
2005-06-22 |
2007-11-28 |
Astrazeneca Ab |
Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
|
AR056866A1
(es)
|
2005-06-22 |
2007-10-31 |
Astrazeneca Ab |
Compuestos quimicos derivados de 2-azetidinona, una formulacion farmaceutica y un proceso de preparacion del compuesto
|
AR057383A1
(es)
|
2005-06-22 |
2007-12-05 |
Astrazeneca Ab |
Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
|
US7067689B1
(en)
*
|
2005-07-08 |
2006-06-27 |
Microbia, Inc. |
Process for production of pentahydroxyhexylcarbamoyl alkanoic acids
|
JP2007022943A
(ja)
|
2005-07-13 |
2007-02-01 |
Dai Ichi Seiyaku Co Ltd |
スクアレン合成酵素阻害薬
|
DE102005033100B3
(de)
|
2005-07-15 |
2007-01-25 |
Sanofi-Aventis Deutschland Gmbh |
Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung
|
DE102005033099A1
(de)
|
2005-07-15 |
2007-01-18 |
Sanofi-Aventis Deutschland Gmbh |
Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindung enthaltende Arzneimittel und dessen Verwendung
|
WO2007015744A1
(en)
|
2005-07-21 |
2007-02-08 |
Incyte Corporation |
Disubstituted thienyl compounds and their use as pharmaceuticals
|
EP2272848B1
(en)
|
2005-08-10 |
2012-12-26 |
Glaxosmithkline LLC |
Xanthine derivatives as selective HM74A agonists
|
GB0516462D0
(en)
|
2005-08-10 |
2005-09-14 |
Smithkline Beecham Corp |
Novel compounds
|
US20090258862A1
(en)
|
2005-08-29 |
2009-10-15 |
Colletti Steven L |
Niacin receptor agonists, compositions containing such compounds and methods of treatment
|
WO2007026761A1
(ja)
|
2005-08-31 |
2007-03-08 |
Astellas Pharma Inc. |
チアゾール誘導体
|
KR20080048520A
(ko)
|
2005-09-29 |
2008-06-02 |
사노피-아벤티스 |
페닐 그룹을 갖는, 페닐- 및 피리딜-1,2,4-옥사디아졸론유도체, 이의 제조 방법 및 약제로서의 이의 용도
|
EP1942904A4
(en)
|
2005-09-30 |
2009-11-18 |
Merck & Co Inc |
CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS
|
DE102005055726A1
(de)
*
|
2005-11-23 |
2007-08-30 |
Sanofi-Aventis Deutschland Gmbh |
Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
US20080319221A1
(en)
|
2007-06-22 |
2008-12-25 |
Bernd Junker |
Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
|
US20080319218A1
(en)
*
|
2007-06-22 |
2008-12-25 |
Andreas Haubrich |
Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate
|
WO2009112203A1
(de)
*
|
2008-03-14 |
2009-09-17 |
Sanofi-Aventis Deutschland Gmbh |
Verfahren zur herstellung eines diphenylazetidinons
|